Syros rises 13% as tamibarotene gets FDA orphan drug status for myelodysplastic syndrome
February 02 2022 - 4:09PM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024